Sensor: ENhancing aSthma carE - An Observational Prospective Study to Characterize Patients Initiating Indacaterol + Glycopyrronium Bromide + Mometasone Furoate (Enerzair, Breezhaler), With or Without Sensor, as a Maintenance Treatment for Asthma
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms SENSE
- Sponsors Novartis Pharmaceuticals
- 22 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Dec 2021 Planned initiation date changed from 15 Nov 2021 to 15 Feb 2022.
- 19 Nov 2021 New trial record